Janus Henderson Group PLC acquired a new stake in shares of Syneos Health Inc (NASDAQ:SYNH) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 25,491 shares of the company’s stock, valued at approximately $1,302,000.
A number of other hedge funds have also recently bought and sold shares of the business. Congress Asset Management Co. MA purchased a new stake in Syneos Health during the second quarter valued at about $3,643,000. JPMorgan Chase & Co. lifted its stake in Syneos Health by 13.2% during the second quarter. JPMorgan Chase & Co. now owns 1,495,906 shares of the company’s stock valued at $74,242,000 after buying an additional 174,481 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Syneos Health by 25.5% during the second quarter. Wells Fargo & Company MN now owns 361,062 shares of the company’s stock valued at $18,446,000 after buying an additional 73,406 shares in the last quarter. AMI Asset Management Corp lifted its stake in Syneos Health by 42.8% during the second quarter. AMI Asset Management Corp now owns 355,755 shares of the company’s stock valued at $18,176,000 after buying an additional 106,594 shares in the last quarter. Finally, Bbva USA Bancshares Inc. lifted its stake in Syneos Health by 2.0% during the second quarter. Bbva USA Bancshares Inc. now owns 16,230 shares of the company’s stock valued at $830,000 after buying an additional 314 shares in the last quarter.
NASDAQ SYNH opened at $54.35 on Friday. The company has a 50 day simple moving average of $51.06 and a 200-day simple moving average of $48.13. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.89 and a quick ratio of 0.89. The firm has a market capitalization of $5.62 billion, a price-to-earnings ratio of 20.74, a price-to-earnings-growth ratio of 1.83 and a beta of 1.51. Syneos Health Inc has a 52-week low of $36.26 and a 52-week high of $56.34.
Syneos Health (NASDAQ:SYNH) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.02. The business had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Syneos Health had a net margin of 0.36% and a return on equity of 9.82%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 earnings per share. On average, analysts predict that Syneos Health Inc will post 2.73 EPS for the current year.
SYNH has been the subject of a number of research analyst reports. Credit Suisse Group increased their price target on shares of Syneos Health from $56.00 to $58.00 and gave the stock an “outperform” rating in a research report on Friday, August 23rd. UBS Group increased their price target on shares of Syneos Health from $53.50 to $57.00 and gave the stock a “neutral” rating in a research report on Thursday, August 29th. SunTrust Banks increased their price target on shares of Syneos Health to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 price target for the company. in a research report on Tuesday. Finally, KeyCorp increased their price target on shares of Syneos Health from $63.00 to $65.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Five equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $58.63.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Further Reading: Front-End Load
Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.